Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$27.7 - $35.48 $177,390 - $227,213
-6,404 Reduced 74.61%
2,179 $63,000
Q4 2023

Feb 14, 2024

BUY
$26.32 - $34.31 $225,904 - $294,482
8,583 New
8,583 $289,000
Q4 2022

Feb 14, 2023

BUY
$38.19 - $57.45 $50,945 - $76,638
1,334 Added 1.24%
109,171 $4.22 Million
Q3 2022

Nov 14, 2022

BUY
$51.24 - $58.89 $3.57 Million - $4.1 Million
69,678 Added 182.6%
107,837 $5.74 Million
Q2 2022

Aug 08, 2022

SELL
$51.49 - $81.64 $4.99 Million - $7.91 Million
-96,868 Reduced 71.74%
38,159 $2.23 Million
Q1 2022

May 16, 2022

BUY
$60.03 - $76.49 $1.2 Million - $1.52 Million
19,930 Added 17.32%
135,027 $10.3 Million
Q4 2021

Mar 03, 2022

BUY
$47.97 - $62.21 $1.17 Million - $1.51 Million
24,315 Added 26.78%
115,097 $6.93 Million
Q3 2021

Nov 15, 2021

SELL
$54.64 - $61.3 $198,671 - $222,886
-3,636 Reduced 3.85%
90,782 $5.08 Million
Q2 2021

Aug 16, 2021

BUY
$59.18 - $69.99 $3.2 Million - $3.78 Million
54,056 Added 133.93%
94,418 $5.73 Million
Q1 2021

May 17, 2021

SELL
$59.31 - $78.82 $259,777 - $345,231
-4,380 Reduced 9.79%
40,362 $2.83 Million
Q4 2020

Feb 16, 2021

BUY
$50.47 - $66.26 $2.26 Million - $2.96 Million
44,742 New
44,742 $2.68 Million
Q2 2020

Aug 14, 2020

SELL
$30.8 - $52.47 $162,624 - $277,041
-5,280 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$28.4 - $50.7 $144,272 - $257,556
5,080 Added 2540.0%
5,280 $177,000
Q4 2019

Feb 14, 2020

BUY
$36.31 - $46.83 $7,262 - $9,366
200 New
200 $9,000
Q3 2019

Nov 14, 2019

SELL
$35.66 - $44.99 $91,860 - $115,894
-2,576 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$36.57 - $47.97 $94,204 - $123,570
2,576 New
2,576 $112,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $892M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.